



Inflammasome as a Promising Therapeutic Target

Guest Editor:

Dr. Sonia Missiroli

Department of Medical Sciences,
Section of Experimental
Medicine, University of Ferrara,
Ferrara, Italy

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Inflammasomes have been associated with the pathogenesis of multiple diseases, including neurodegenerative diseases (multiple sclerosis, Alzheimer's disease, and Parkinson's disease), autoimmune diseases, metabolic disorders, and cancer. Thus, considering the substantial role of inflammasomes in different inflammatory pathologies, it is not surprising that strategies targeting inflammasomes are a hot topic of research.

The aim of this Special Issue is to collect the latest reports on the role of inflammasomes in several human pathologies, with particular emphasis on the possible therapeutic values in targeting these inflammasomes for the prevention and treatment of these diseases. A greater understanding of the signaling molecules mediating the beneficial and detrimental effects of their activation is needed.

This Special Issue will provide insights regarding the clinical relevance of inflammasomes in human diseases, highlighting their therapeutic promise as molecular targets.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI